L Number	Hits	Search Text	DB	Time stamp
-	8902	(cell ADJ culture) SAME recombinant SAME (protein OR polypeptide)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/07 18:24
-	2	(cell ADJ culture) SAME recombinant SAME (protein OR polypeptide) SAME cytidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/29 11:01
-	1	(demethylating ADJ agent) SAME cytidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/29 11:03
-	182	(demethylating ADJ agent)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/29 11:03
-	3	"5851773"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/29 11:12
-	2	"5851773" AND demethylating	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/29 11:14
-	1	WO-200129235-$.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/06 14:15
-	24	reddy-p.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/06 14:11
-	61	rasmussen-b$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/06 14:11
-	0	rasmussen-brian.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/06 14:11
-	11	reddy-pranhitha.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/06 14:11
-	0	"5-bromo-2'-deoxycytidine" SAME (CHO OR (chinese ADJ hamster ADJ ovary))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/06 14:17
-	0	"5-aza-2'-deoxycytidine" SAME (CHO OR (chinese ADJ hamster ADJ ovary))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/06 14:17
-	0	rasmussen-brian.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 07:53
-	62	rasmussen-b$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 07:53
-	11	reddy-pranhitha.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:19
-	9	(reddy-pranhitha.in. OR rasmussen-b$.in.) AND cell ADJ culture	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 07:56

-	62886	cell ADJ culture	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 07:56
-	9061	(cell ADJ culture).ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 07:56
-	30	(cell ADJ culture).ab. AND cytidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:25
-	11	(cell ADJ culture).ab. AND cytidine AND chinese ADJ hamster ADJ ovary	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 07:58
-	5	(demethylating ADJ agent) SAME cell ADJ culture	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:00
-	0	(recombinant ADJ protein) SAME (CHO OR chinese ADJ hamster ADJ ovary) SAME (serum ADJ free ADJ medium) SAME (demethylating)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:06
-	6	("5-aza-2'-deoxycytidine" OR "5-bromo-2'-deoxycytidine") AND (recombinant ADJ protein ADJ production)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:07
-	0	(recombinant ADJ protein) SAME (CHO OR chinese ADJ hamster ADJ ovary) SAME (serum ADJ free ADJ medium) SAME (demethylating ADJ agent)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:08
-	10	(recombinant ADJ protein) SAME (CHO OR chinese ADJ hamster ADJ ovary) SAME (serum ADJ free ADJ medium)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:08
-	999	(recombinant ADJ protein) AND (CHO OR chinese ADJ hamster ADJ ovary) AND (serum ADJ free ADJ medium)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:10
-	3663	(cell ADJ culture) SAME recombinant SAME (protein OR polypeptide) AND 435/69.1.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:10
-	34	(immuglobulin OR antibody) SAME (recombinant ADJ protein ADJ production)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:10
-	0	demethylating SAME recombinant SAME (protein OR polypeptide)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:12
-	175	"5-bromo-2'-deoxycytidine"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:13
-	205	"5-aza-2'-deoxycytidine"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:16
-	205	decitabine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:16
-	13	decitabine AND chinese ADJ hamster ADJ ovary	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 09:19
-	5	663853.ap.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:19

-	1	(recombinant ADJ protein) AND (CHO OR chinese ADJ hamster ADJ ovary) AND "5-aza-2'-deoxycytidine" AND (serum ADJ free ADJ medium)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:19
-	3	"6413744"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 08:35
-	0	536/26.3.ccls. AND chinese ADJ hamster ADJ ovary	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 09:19
-	55	536/22.1.ccls. AND chinese ADJ hamster ADJ ovary	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 09:20
-	243	435/358.ccls. AND chinese ADJ hamster ADJ ovary	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 09:20
-	89	435/358.ccls. AND chinese ADJ hamster ADJ ovary AND (recombinant ADJ protein)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/26 09:21

PubMed

National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for Preview Go Clear

Limits Preview/Index **History** Clipboard Details

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Search	Most Recent Queries	Time	Result
#7	Search **chinese hamster ovary cells AND decitabine**	09:29:40	8
#6	Search **chinese hamster ovary cells AND serum free AND decitabine**	09:29:28	0
#5	Search **chinese hamster ovary cells AND serum free AND cytodine**	09:28:57	0
#4	Search **chinese hamster ovary cells AND serum free AND 5-aza-2'-deoxycytidine**	09:28:44	0
#3	Search **chinese hamster ovary cells AND serum free AND cytidine analogue**	09:28:21	0
#2	Search **chinese hamster ovary cells AND serum free**	09:28:06	213
#1	Search **chinese hamster ovary cells**	09:27:58	12965

Clear History

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Oct 13 2004 06:44:09

h cb hg e e e fcg b e

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653aud

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  Jul 12   BEILSTEIN enhanced with new display and select options,
                   resulting in a closer connection to BABS
 NEWS  4  AUG 02   IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                   fields
 NEWS  5  AUG 02   CAplus and CA patent records enhanced with European and Japan
                   Patent Office Classifications
 NEWS  6  AUG 02   The Analysis Edition of STN Express with Discover!
                   (Version 7.01 for Windows) now available
 NEWS  7  AUG 27   BIOCOMMERCE: Changes and enhancements to content coverage
 NEWS  8  AUG 27   BIOTECHABS/BIOTECHDS: Two new display fields added for legal
                   status data from INPADOC
 NEWS  9  SEP 01   INPADOC: New family current-awareness alert (SDI) available
 NEWS 10  SEP 01   New pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover!
 NEWS 11  SEP 01   New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
 NEWS 12  SEP 27   STANDARDS will no longer be available on STN
 NEWS 13  SEP 27   SWETSCAN will no longer be available on STN

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:37:52 ON 26 OCT 2004

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21
```

```
INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
      AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
      BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
      CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 09:38:00 ON 26 OCT 2004

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> cytidine
CYTIDINE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s cytidine
        110   FILE ADISCTI
         17   FILE ADISINSIGHT
          3   FILE ADISNEWS
        242   FILE AGRICOLA
        245   FILE ANABSTR
         42   FILE AQUASCI
         88   FILE BIOBUSINESS
         11   FILE BIOCOMMERCE
        151   FILE BIOENG
       6245   FILE BIOSIS
        316   FILE BIOTECHABS
        316   FILE BIOTECHDS
       2418   FILE BIOTECHNO
        424   FILE CABA
       1735   FILE CANCERLIT
      12115   FILE CAPLUS
         39   FILE CEABA-VTB
          5   FILE CEN
          9   FILE CIN
         84   FILE CONFSCI
          9   FILE CROPB
         14   FILE CROPU
        776   FILE DDFB
        776   FILE DDFU
       3156   FILE DGENE
        314   FILE DISSABS
        776   FILE DRUGB
         41   FILE DRUGMONOG2
        993   FILE DRUGU
         40   FILE EMBAL
       6431   FILE EMBASE
       1254   FILE ESBIOBASE
         48   FILE FEDRIP
         22   FILE FROSTI
         64   FILE FSTA
        961   FILE GENBANK
          8   FILE HEALSAFE
        673   FILE IFIPAT
         15   FILE IMSDRUGNEWS
         10   FILE IMSPRODUCT
        235   FILE JICST-EPLUS
       1526   FILE LIFESCI
  49 FILES SEARCHED...
       6894   FILE MEDLINE
         88   FILE NIOSHTIC
```

```
          66   FILE NTIS
          13   FILE OCEAN
        2614   FILE PASCAL
          23   FILE PHAR
           5   FILE PHARMAML
          15   FILE PHIN
          96   FILE PROMT
         108   FILE PROUSDDR
           4   FILE PS
           1   FILE RDISCLOSURE
        3717   FILE SCISEARCH
          14   FILE SYNTHLINE
        4647   FILE TOXCENTER
        6361   FILE USPATFULL
         287   FILE USPAT2
           3   FILE VETB
           5   FILE VETU
           3   FILE WATER
         966   FILE WPIDS
           4   FILE WPIFV
         966   FILE WPINDEX

  65 FILES HAVE ONE OR MORE ANSWERS,   75 FILES SEARCHED IN STNINDEX

L1   QUE CYTIDINE

=> d rank
F1       12115   CAPLUS
F2        6894   MEDLINE
F3        6431   EMBASE
F4        6361   USPATFULL
F5        6245   BIOSIS
F6        4647   TOXCENTER
F7        3717   SCISEARCH
F8        3156   DGENE
F9        2614   PASCAL
F10       2418   BIOTECHNO
F11       1735   CANCERLIT
F12       1526   LIFESCI
F13       1254   ESBIOBASE
F14        993   DRUGU
F15        966   WPIDS
F16        966   WPINDEX
F17        961   GENBANK
F18        776   DDFB
F19        776   DDFU
F20        776   DRUGB
F21        673   IFIPAT
F22        424   CABA
F23        316   BIOTECHABS
F24        316   BIOTECHDS
F25        314   DISSABS
F26        287   USPAT2
F27        245   ANABSTR
F28        242   AGRICOLA
F29        235   JICST-EPLUS
F30        151   BIOENG
F31        110   ADISCTI
F32        108   PROUSDDR
F33         96   PROMT
F34         88   BIOBUSINESS
F35         88   NIOSHTIC
F36         84   CONFSCI
```

```
F37          66   NTIS
F38          64   FSTA
F39          48   FEDRIP
F40          42   AQUASCI
F41          41   DRUGMONOG2
F42          40   EMBAL
F43          39   CEABA-VTB
F44          23   PHAR
F45          22   FROSTI
F46          17   ADISINSIGHT
F47          15   IMSDRUGNEWS
F48          15   PHIN
F49          14   CROPU
F50          14   SYNTHLINE
F51          13   OCEAN
F52          11   BIOCOMMERCE
F53          10   IMSPRODUCT
F54           9   CIN
F55           9   CROPB
F56           8   HEALSAFE
F57           5   CEN
F58           5   PHARMAML
F59           5   VETU
F60           4   PS
F61           4   WPIFV
F62           3   ADISNEWS
F63           3   VETB
F64           3   WATER
F65           1   RDISCLOSURE


=> file f1, f2, f3, f4, f5, f6, f7, f8, f9, f10, f11
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                               ENTRY    SESSION
FULL ESTIMATED COST                             1.71       1.92

FILE 'CAPLUS' ENTERED AT 09:39:29 ON 26 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:39:29 ON 26 OCT 2004

FILE 'EMBASE' ENTERED AT 09:39:29 ON 26 OCT 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'USPATFULL' ENTERED AT 09:39:29 ON 26 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:39:29 ON 26 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'TOXCENTER' ENTERED AT 09:39:29 ON 26 OCT 2004
COPYRIGHT (C) 2004 ACS

FILE 'SCISEARCH' ENTERED AT 09:39:29 ON 26 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'DGENE' ENTERED AT 09:39:29 ON 26 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'PASCAL' ENTERED AT 09:39:29 ON 26 OCT 2004
Any reproduction or dissemination in part or in full,
```

FILE 'BIOTECHNO' ENTERED AT 09:39:29 ON 26 OCT 2004

FILE 'CANCERLIT' ENTERED AT 09:39:29 ON 26 OCT 2004

```
=> s decitabine
L2         1065 DECITABINE

=> s cell(w)culture AND chinese(w)hamster(w)ovary
    4 FILES SEARCHED...
    7 FILES SEARCHED...
    8 FILES SEARCHED...
   10 FILES SEARCHED...
L3        18741 CELL(W) CULTURE AND CHINESE(W) HAMSTER(W) OVARY

=> L3 AND L2
L3 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s L3 AND L2
L4           12 L3 AND L2

=> dup rem l4
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4
L5           12 DUP REM L4 (0 DUPLICATES REMOVED)

=> d l5 ibib ti abs 1-12

L5   ANSWER 1 OF 12  USPATFULL on STN
ACCESSION NUMBER:        2004:267333  USPATFULL
TITLE:                   Stabilized high concentration anti-integrin
                         alphanubeta3 antibody formulations
INVENTOR(S):             Allan, Christian B., Brookeville, MD, UNITED STATES
PATENT ASSIGNEE(S):      MedImmune, Inc. (U.S. corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004208870      A1   20041021
APPLICATION INFO.:       US 2004-769712     A1   20040130  (10)

                               NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2003-443777P    20030130 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS:        55
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      1 Drawing Page(s)
LINE COUNT:              6217
TI     Stabilized high concentration anti-integrin alphanubeta3 antibody
       formulations
AB     The present invention provides liquid formulations of antibodies or
       antibody fragments that immunospecifically bind to integrin
       α.sub.Vβ.sub.3, which formulations exhibit stability, low to
```

undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin α.sub.Vβ.sub.3, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin α.sub.Vβ.sub.3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

L5 ANSWER 2 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2004:267332 USPATFULL		
TITLE:	Uses of anti-integrin alphanubeta3 antibody formulations		
INVENTOR(S):	Allan, Christian B., Brookeville, MD, UNITED STATES		
PATENT ASSIGNEE(S):	MedImmune, Inc. (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004208869	A1	20041021
APPLICATION INFO.:	US 2004-769700	A1	20040130 (10)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2003-443810P		20030130 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017		
NUMBER OF CLAIMS:	40		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	6223		

TI Uses of anti-integrin alphanubeta3 antibody formulations

AB The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin α.sub.vβ.sub.3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin α.sub.vβ.sub.3, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin α.sub.vβ.sub.3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

L5 ANSWER 3 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2004:261855 USPATFULL
TITLE:	Modulator of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
INVENTOR(S):	Brautigam, Matthias, Berlin, GERMANY, FEDERAL REPUBLIC OF

Zerhusen, Sandra, Berlin, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004204357	A1	20041014
APPLICATION INFO.:	US 2004-754103	A1	20040109 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2003-6592	20030324
	US 2003-457999P	20030328 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 5045

TI Modulator of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics

AB The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of cancer disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis of radiopharmaceutics into cells of the kidney and the subsequent radioinduced damaging of the kidney catabolism by blocking or interfering with the association or binding of radiotherapeutics and/or radiodiagnostics to the receptor megalin, a member of the LDL-receptor family. In another aspect of the present invention, the expression of megalin is altered, in order to prevent the endocytosis and cellular internalisation of radiopharmaceutics into cells of the kidney.

L5 ANSWER 4 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:239241 USPATFULL
TITLE: FcgammaRIIB-specific antibodies and methods of use thereof
INVENTOR(S): Koenig, Scott, Rockville, MD, UNITED STATES
Veri, Maria Concetta, Derwood, MD, UNITED STATES
PATENT ASSIGNEE(S): MacroGenics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004185045	A1	20040923
APPLICATION INFO.:	US 2003-643857	A1	20030814 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-403266P	20020814 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 107
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Page(s)
LINE COUNT: 7320
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI FcgammaRIIB-specific antibodies and methods of use thereof

AB The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides

methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:177787 USPATFULL
TITLE: Death domain containing receptor 5
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte, BRAZIL
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004136951	A1	20040715
APPLICATION INFO.:	US 2003-648825	A1	20030827 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-565009, filed on 4 May 2000, PENDING Continuation-in-part of Ser. No. US 1998-42583, filed on 17 Mar 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-413747P	20020927 (60)
	US 2002-406307P	20020828 (60)
	US 1999-148939P	19990813 (60)
	US 1999-133238P	19990507 (60)
	US 1999-132498P	19990504 (60)
	US 1997-54021P	19970729 (60)
	US 1997-40846P	19970317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 12832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Death domain containing receptor 5
AB The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which maybe agonists and/or antagonists of DR5 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:177786 USPATFULL
TITLE: Death domain containing receptor 4
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	Gentz, Reiner L., Belo-Horizonte, BRAZIL
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc. (U.S. corporation) The Regents of the University of Michigan (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004136950	A1	20040715	
APPLICATION INFO.:	US 2003-648786	A1	20030827	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-565918, filed on 5 May 2000, GRANTED, Pat. No. US 6433147 Continuation-in-part of Ser. No. US 1998-13895, filed on 27 Jan 1998, GRANTED, Pat. No. US 6342363			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-413861P	20020927	(60)
	US 2002-406922P	20020830	(60)
	US 1999-132922P	19990506	(60)
	US 1997-37829P	19970205	(60)
	US 1997-35722P	19970128	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVE., N.W., WASHINGTON, DC, 20005
NUMBER OF CLAIMS:	77
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Page(s)
LINE COUNT:	13407

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Death domain containing receptor 4

AB The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2004:177744 USPATFULL
TITLE:	Anti-cd19 immunotoxins
INVENTOR(S):	Olson, William C., Issububg, NY, UNITED STATES Maddon, Paul J., Scarsdale, NY, UNITED STATES Ma, Dangshe, Millwood, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004136908	A1	20040715	
APPLICATION INFO.:	US 2004-474469	A1	20040304	(10)
	WO 2002-US9889		20020329	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60282587	20010904

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION

LEGAL REPRESENTATIVE: WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211
NUMBER OF CLAIMS: 115
EXEMPLARY CLAIM: 1
LINE COUNT: 1635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Anti-cd19 immunotoxins
AB The invention relates to therapeutic methods using compositions including immunotoxins based on antibodies that specifically bind the B cell membrane protein CD19. Anti-CD19 immunotoxins, compositions containing such immunotoxins, and methods for using the immunotoxins are provided. Use of immunotoxins in the manufacture of medicaments for the treatment of various disorders also is provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:120080 USPATFULL
TITLE: EphA2 agonistic monoclonal antibodies and methods of use thereof
INVENTOR(S): Kinch, Michael S., Laytonsville, MD, UNITED STATES
Carles-Kinch, Kelly, Laytonsville, MD, UNITED STATES
Stewart, Jane C., West Lafayette, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004091486	A1	20040513
APPLICATION INFO.:	US 2003-436783	A1	20030512 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-379368P	20020510 (60)
	US 2002-418204P	20021014 (60)
	US 2003-460358P	20030403 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST STREET, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 69
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Page(s)
LINE COUNT: 4227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI EphA2 agonistic monoclonal antibodies and methods of use thereof
AB The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:38149 USPATFULL
TITLE: EphA2 monoclonal antibodies and methods of use thereof
INVENTOR(S): Kinch, Michael S., Laytonsville, MD, UNITED STATES
Carles-Kinch, Kelly, Laytonsville, MD, UNITED STATES
Kiener, Peter, Potomac, MD, UNITED STATES

Langermann, Solomon, Baltimore, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004028685	A1	20040212
APPLICATION INFO.:	US 2003-436782	A1	20030512 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-379322P	20020510 (60)
	US 2002-418213P	20021014 (60)
	US 2003-460507P	20030403 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS: 95
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 5596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI EphA2 monoclonal antibodies and methods of use thereof

AB The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low K.sub.off, thereby, inhibiting tumor cell growth and/or metastasis. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:1816 USPATFULL
TITLE: Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
INVENTOR(S): Woessner, Richard, Lafayette, CO, UNITED STATES
Kiener, Peter, Doylestwon, PA, UNITED STATES
Dormitzer, Melissa, Germantown, MD, UNITED STATES
Walsh, William, Sharpsburg, MD, UNITED STATES
Heinrichs, Jon, North Potomac, MD, UNITED STATES
PATENT ASSIGNEE(S): MedImmune, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004001835	A1	20040101
APPLICATION INFO.:	US 2003-379189	A1	20030304 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-361859P	20020304 (60)
	US 2002-370398P	20020405 (60)
	US 2003-444265P	20030130 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 6588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
AB The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin α.sub.Vβ.sub.3 alone or in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more antagonists of Integrin α.sub.Vβ.sub.3 and/or one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of a therapeutically or prophylactically effective amount of one or more antagonists of Integrin α.sub.Vβ.sub.3 alone or in combination with standard and experimental therapies for treatment or prevention of cancer. Also included are methods for screening for epitope-specific Integrin α.sub.Vβ.sub.3 antagonists which can be used according to the methods of the invention. In addition, methods for facilitating the use of Integrin α.sub.Vβ.sub.3 antagonists in the analysis of Integrin α.sub.Vβ.sub.3 expression in biopsies of animal model and clinical study samples are also contemplated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2003:65373 USPATFULL
TITLE: Methylation resistant vectors
INVENTOR(S): Widegren, Bengt, Lund, SWEDEN
Persson, Bertil, Lund, SWEDEN
Salford, Leif G., Lund, SWEDEN
PATENT ASSIGNEE(S): Geneinvent BBL AB (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003045497	A1	20030306	
APPLICATION INFO.:	US 2002-206557	A1	20020726	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-308549P	20010727 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: David D. Stein, BOYLE, FREDRICKSON, NEWHOLM, STEIN & GRATZ, S.C., 250 Plaza, Suite 1030, 250 East Wisconsin Avenue, Milwaukee, WI, 53202
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Methylation resistant vectors
AB The invention relates to vectors produced in a donor host cell, which upon transfer into a receiver host cell maintain the desired expression

of the nucleotide sequences that are located within the vector. The maintenance of the desired expression is achieved because the vector at least partly remains unmethylated within the receiver host cell. The donor host cell is different as compared to the receiver host cell and the receiver host cell being capable of methylating DNA. The invention also relates to methods for the production of such vectors and the use of the vectors in industry as well as in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2002:194380 USPATFULL			
TITLE:	Implantable prosthetic devices coated with bioactive molecules			
INVENTOR(S):	Valentini, Robert F., Cranston, RI, United States			
PATENT ASSIGNEE(S):	Brown University Research Foundation, Providence, RI, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6428579	B1	20020806	
	WO 9901089		19990114	
APPLICATION INFO.:	US 1999-446942		19991229	(9)
	WO 1998-US13792		19980701	
			20000512	PCT 371 date
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Willse, David H.			
ASSISTANT EXAMINER:	Jackson, Suzette J.			
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.			
NUMBER OF CLAIMS:	39			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)			
LINE COUNT:	2236			

TI Implantable prosthetic devices coated with bioactive molecules

AB Coated implantable prosthetic devices are disclosed. The device is a prosthetic having a gold layer on the surface to which bioactive molecules are attached through a gold-sulfhydryl bond. The devices are easy and convenient to prepare. Gold coated implantable devices are also disclosed herein. The gold coated implantable device is a prosthetic device formed of a porous non-fabric material having a surface with projections and indentations and the gold layer on the surface of the porous non-fabric material forms a uniform layer across the material such that the gold layer also forms projections and indentations.

=> d his

(FILE 'HOME' ENTERED AT 09:37:52 ON 26 OCT 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 09:38:00 ON 26 OCT 2004

	SEA CYTIDINE
110	FILE ADISCTI
17	FILE ADISINSIGHT
3	FILE ADISNEWS
242	FILE AGRICOLA
245	FILE ANABSTR
42	FILE AQUASCI

```
      88   FILE BIOBUSINESS
      11   FILE BIOCOMMERCE
     151   FILE BIOENG
    6245   FILE BIOSIS
     316   FILE BIOTECHABS
     316   FILE BIOTECHDS
    2418   FILE BIOTECHNO
     424   FILE CABA
    1735   FILE CANCERLIT
   12115   FILE CAPLUS
      39   FILE CEABA-VTB
       5   FILE CEN
       9   FILE CIN
      84   FILE CONFSCI
       9   FILE CROPB
      14   FILE CROPU
     776   FILE DDFB
     776   FILE DDFU
    3156   FILE DGENE
     314   FILE DISSABS
     776   FILE DRUGB
      41   FILE DRUGMONOG2
     993   FILE DRUGU
      40   FILE EMBAL
    6431   FILE EMBASE
    1254   FILE ESBIOBASE
      48   FILE FEDRIP
      22   FILE FROSTI
      64   FILE FSTA
     961   FILE GENBANK
       8   FILE HEALSAFE
     673   FILE IFIPAT
      15   FILE IMSDRUGNEWS
      10   FILE IMSPRODUCT
     235   FILE JICST-EPLUS
    1526   FILE LIFESCI
    6894   FILE MEDLINE
      88   FILE NIOSHTIC
      66   FILE NTIS
      13   FILE OCEAN
    2614   FILE PASCAL
      23   FILE PHAR
       5   FILE PHARMAML
      15   FILE PHIN
      96   FILE PROMT
     108   FILE PROUSDDR
       4   FILE PS
       1   FILE RDISCLOSURE
    3717   FILE SCISEARCH
      14   FILE SYNTHLINE
    4647   FILE TOXCENTER
    6361   FILE USPATFULL
     287   FILE USPAT2
       3   FILE VETB
       5   FILE VETU
       3   FILE WATER
     966   FILE WPIDS
       4   FILE WPIFV
     966   FILE WPINDEX
L1          QUE CYTIDINE
            ---------

FILE 'CAPLUS, MEDLINE, EMBASE, USPATFULL, BIOSIS, TOXCENTER, SCISEARCH,
```

```
     DGENE, PASCAL, BIOTECHNO, CANCERLIT' ENTERED AT 09:39:29 ON 26 OCT 2004
L2          1065 S DECITABINE
L3         18741 S CELL(W)CULTURE AND CHINESE(W)HAMSTER(W)OVARY
L4            12 S L3 AND L2
L5            12 DUP REM L4 (0 DUPLICATES REMOVED)

=> s L3 AND serum(w)free
L6          5416 L3 AND SERUM(W) FREE

=> S L6 AND L2
L7             4 L6 AND L2

=> d l7 ibibi ti abs 1-4
'IBIBI' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
             EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
             PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE".  BROWSE must
             entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
             PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,
             NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
             CLMN, DRWN, AB
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
             RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,
             NCLS, EXF, REP, REN,ARTU, EXNAM, LREP, CLMN, DRWN, AB,
             PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
             RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
             its structure diagram
FPG -------- FP plus PAGE.DRAW
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
```

EXF, ARTU, OS, CC, SX, ST, IT
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL, DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS, EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI, DT, FS, LN.CNT
SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display without answer number. SCAN must be entered on the same line as DISPLAY, e.g., D SCAN)
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI, DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS

ENTER DISPLAY FORMAT (STD):abs

L7 ANSWER 1 OF 4 USPATFULL on STN
AB The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of cancer disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis of radiopharmaceutics into cells of the kidney and the subsequent radioinduced damaging of the kidney catabolism by blocking or interfering with the association or binding of radiotherapeutics and/or radiodiagnostics to the receptor megalin, a member of the LDL-receptor family. In another aspect of the present invention, the expression of megalin is altered, in order to prevent the endocytosis and cellular internalisation of radiopharmaceutics into cells of the kidney.

L7 ANSWER 2 OF 4 USPATFULL on STN
AB The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which maybe agonists and/or antagonists of DR5 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 4 USPATFULL on STN
AB The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists

and/or antagonists of DR4 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 4 USPATFULL on STN

AB Coated implantable prosthetic devices are disclosed. The device is a prosthetic having a gold layer on the surface to which bioactive molecules are attached through a gold-sulfhydryl bond. The devices are easy and convenient to prepare. Gold coated implantable devices are also disclosed herein. The gold coated implantable device is a prosthetic device formed of a porous non-fabric material having a surface with projections and indentations and the gold layer on the surface of the porous non-fabric material forms a uniform layer across the material such that the gold layer also forms projections and indentations.

=> d his

(FILE 'HOME' ENTERED AT 09:37:52 ON 26 OCT 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 09:38:00 ON 26 OCT 2004

SEA CYTIDINE

110	FILE ADISCTI
17	FILE ADISINSIGHT
3	FILE ADISNEWS
242	FILE AGRICOLA
245	FILE ANABSTR
42	FILE AQUASCI
88	FILE BIOBUSINESS
11	FILE BIOCOMMERCE
151	FILE BIOENG
6245	FILE BIOSIS
316	FILE BIOTECHABS
316	FILE BIOTECHDS
2418	FILE BIOTECHNO
424	FILE CABA
1735	FILE CANCERLIT
12115	FILE CAPLUS
39	FILE CEABA-VTB
5	FILE CEN
9	FILE CIN
84	FILE CONFSCI
9	FILE CROPB
14	FILE CROPU
776	FILE DDFB
776	FILE DDFU
3156	FILE DGENE
314	FILE DISSABS
776	FILE DRUGB
41	FILE DRUGMONOG2
993	FILE DRUGU
40	FILE EMBAL
6431	FILE EMBASE
1254	FILE ESBIOBASE
48	FILE FEDRIP
22	FILE FROSTI
64	FILE FSTA
961	FILE GENBANK

```
                8   FILE HEALSAFE
              673   FILE IFIPAT
               15   FILE IMSDRUGNEWS
               10   FILE IMSPRODUCT
              235   FILE JICST-EPLUS
             1526   FILE LIFESCI
             6894   FILE MEDLINE
               88   FILE NIOSHTIC
               66   FILE NTIS
               13   FILE OCEAN
             2614   FILE PASCAL
               23   FILE PHAR
                5   FILE PHARMAML
               15   FILE PHIN
               96   FILE PROMT
              108   FILE PROUSDDR
                4   FILE PS
                1   FILE RDISCLOSURE
             3717   FILE SCISEARCH
               14   FILE SYNTHLINE
             4647   FILE TOXCENTER
             6361   FILE USPATFULL
              287   FILE USPAT2
                3   FILE VETB
                5   FILE VETU
                3   FILE WATER
              966   FILE WPIDS
                4   FILE WPIFV
              966   FILE WPINDEX
L1               QUE CYTIDINE
                 ---------

     FILE 'CAPLUS, MEDLINE, EMBASE, USPATFULL, BIOSIS, TOXCENTER, SCISEARCH,
     DGENE, PASCAL, BIOTECHNO, CANCERLIT' ENTERED AT 09:39:29 ON 26 OCT 2004
L2          1065 S DECITABINE
L3         18741 S CELL(W)CULTURE AND CHINESE(W)HAMSTER(W)OVARY
L4            12 S L3 AND L2
L5            12 DUP REM L4 (0 DUPLICATES REMOVED)
L6          5416 S L3 AND SERUM(W)FREE
L7             4 S L6 AND L2

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    55.21      57.13

STN INTERNATIONAL LOGOFF AT 09:48:31 ON 26 OCT 2004
```